Editas Medicine opens up the opportunities to develop best-in-class medicines for hemoglobinopathies
The pre-clinical data by Editas Medicine supports novel approach for treatment of sickle cell disease and beta-thalassemia. Editas Medicine, Inc., a leading genome editing company, recently shared outcomes from experiments to demonstrate expanded CRISPR genome editing strategies in hematopoietic stem cells for the treatment of sickle cell disease and beta-thalassemia. In these experiments, the Cambridge, […]











